Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Target Fortification of Breast Milk: How Often Breast Milk Needs to be Measured? (TFO2)

10 de agosto de 2016 atualizado por: Christoph Fusch, McMaster Children's Hospital

Target Fortification of Breast Milk: The Effect of Different Schedules for Milk Analysis on the Growth and Development of Preterm Infants.

It has been observed that target fortification on different schedules leads to meal to meal variation. It changes the ratio of protein to energy and the percentage of carbohydrate to non-protein energy which may, affect growth. In the past, the investigators have analyzed the outcomes of breast milk composition when target fortification is done with different analysis schedules. The investigators were able to measure the macronutrient intake for different milk analysis schedules via a theoretical model and show that the more frequent schedules reduce the variation of fortified-breast milk, whereas a reduced schedule leads to a high variation of macronutrients. It was observed that, in all the breast milk samples measured twice per week, infants achieved on average the recommended macronutrients in line with current recommendations. Nonetheless, the model only looks at the macronutrient intake and does not investigates the relationship between macronutrient variation and its effect on growth.

The aim of the current study is to compare a frequent schedule of measurement of macronutrient analysis with a reduced schedule of measurement and to study its affect on growth, protein accretion and metabolic parameter.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Antecipado)

56

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Ontario
      • Hamilton, Ontario, Canadá, L8S 4K1
        • Faculty of Health Science, McMaster Children's Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

Não mais velho que 6 meses (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Gestational age < 30 weeks (maternal dates or early fetal ultrasound);
  2. Tolerating an enteral intake of ≥100 mL/kg/d for ≥ 24h;
  3. Subject is anticipated to receive the intervention for ≥ 3 consecutive weeks after full enteral feeding (≥150 mL/kg/d) has been achieved;
  4. Written informed consent has been obtained from the infant's legal representative.
  5. Multiple births: Each infant will be included in the study if he/she meets the study criteria, and siblings will be individually randomized to one or other of the treatment arms.
  6. Discussion with Most Responsible Physician (MRP) and the staff in order to discuss any potential transfer during the next 7 days.

Exclusion Criteria:

  1. Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities;
  2. Babies with enterostoma or short gut syndrome;
  3. Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk;
  4. Fluid restriction <140 mL/kg/d for ≥ 3 consecutive days;
  5. Sepsis - all infants with gram-negative sepsis will be removed from the study;
  6. Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3);
  7. Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen >10 mmol/L and creatinine of 130mmol/L
  8. Participation in another clinical trial that may provide an alternative nutritional intervention, which might affect the outcomes of this study. outcomes of this study;
  9. Probability of transfer to another neonatal intensive care unit or level II nursery outside the McMaster Children's Hospital, as discussed with the most responsible physician (MRP)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: 5 milk analysis
  1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.
  2. Routine fortifier will be added to breast milk batches.
  3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Experimental: 1 milk analysis
  1. Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.
  2. Routine fortifier will be added to breast milk batches.
  3. Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Growth during first three weeks of intervention
Prazo: first three weeks during intervention before 36 weeks of gestation
first three weeks during intervention before 36 weeks of gestation

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Daily Nutrient intake (kcal, lactose, protein, fat) measured with conventional milk analysis
Prazo: from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
Weight Gain
Prazo: from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
Oxidative stress by 8-Oxo-2'-deoxyguanosine metabolites in urine
Prazo: from inclusion at postmenstrual age <30 weeks until discharge
Measured by mass spectroscopy
from inclusion at postmenstrual age <30 weeks until discharge
Protein synthesis analyzed by nitrogen excretion in urine [µmol/mL]
Prazo: first three weeks during intervention before 36 weeks of gestation
first three weeks during intervention before 36 weeks of gestation
Feeding intolerance questionaire
Prazo: from inclusion at postmenstrual age <30 weeks until discharge
volume of gastric residuals, color of gastric residuals, vomiting, abdominal girth, abdominal distention
from inclusion at postmenstrual age <30 weeks until discharge
Fat mass [g]
Prazo: from inclusion at postmenstrual age <30 weeks until discharge
Measured with bioelectrical impedance analysis
from inclusion at postmenstrual age <30 weeks until discharge
Lean mass [g]
Prazo: from inclusion at postmenstrual age <30 weeks until discharge
Measured with bioelectrical impedance analysis
from inclusion at postmenstrual age <30 weeks until discharge
Head circumference [cm]
Prazo: from inclusion at postmenstrual age <30 weeks until discharge
Measured by tape
from inclusion at postmenstrual age <30 weeks until discharge
Body length [cm]
Prazo: from inclusion at postmenstrual age <30 weeks until discharge
Measured by length board
from inclusion at postmenstrual age <30 weeks until discharge

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Christoph Fusch, MD, PhD, McMaster Children's Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de setembro de 2016

Conclusão Primária (Antecipado)

1 de junho de 2017

Conclusão do estudo (Antecipado)

1 de junho de 2019

Datas de inscrição no estudo

Enviado pela primeira vez

8 de agosto de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de agosto de 2016

Primeira postagem (Estimativa)

15 de agosto de 2016

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

15 de agosto de 2016

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de agosto de 2016

Última verificação

1 de agosto de 2016

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 2016TFO2

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever